Tuesday 21st August 2012
|Text too small?|
Ebos Group, the medical equipment and consumables distributor that expanded into pet products last year, is targeting growth in its animal health business after the acquisition of the Masterpet business helped lift annual profit by 19 percent.
Net profit from continuing operations rose to $27.9 million, or 53.6 cents per share, in the 12 months ended June 30, from $23.4 million, or 45.4 cents, a year earlier, the Christchurch-based company said in a statement. That was just ahead of the consensus forecast of $27.1 million, or 52 cents per share. Including Ebos' scientific business, which was sold last year, net profit fell 12 percent.
"Our Masterpet acquisition is fully meeting expectations and has made a welcome addition to group profitability," the company said. "Our core healthcare business once again demonstrated the merit of our diverse business model operating across multiple touchpoints in healthcare."
The shares fell 1.2 percent to $7.95 in trading after the announcement, and have gained 21 percent this year. The stock is rated an average 'buy' based on two analyst recommendations compiled by Reuters.
Total revenue rose 6.3 percent to $1.43 billion, in line with the consensus forecast of $1.44 billion. The healthcare unit contributed $1.34 billion and the animal care business $86.4 million.
The healthcare unit's earnings before interest, tax, depreciation and amortisation fell 11 percent to $36.7 million, while the animal unit's ebitda was $10.1 million.
The Masterpet acquisition was projected to add about $170 million of revenue and $20 million of ebitda in the first full year ending June 30, 2013.
"As signalled at the half year, we will be looking to Masterpet and other opportunities in the animal health sector to provide some income growth," the company said.
The healthcare unit faced a short-term cap on growth and increasing margin pressure as the sector undergoes significant reform on both sides of the Tasman, Ebos said.
The board declared a fully-imputed final dividend of 20.5 cents per share, payable on Oct. 5. That takes the annual payment to 34 cents per share, or $17.7 million.
No comments yet
Ebos still hungry for acquisitions after $1.1 bln Symbion deal, Waller says
Ebos meets prospectus forecast with 5.5 percent gain in FY profit
Ebos shareholders approve $1.1 billion purchase of Symbion
Ebos grabs scale with $1.1 bln purchase of Aussie pharma distributor Symbion
Ebos kicks tyres on potential acquisitions
Ebos funding line smaller than previously flagged at $135 mln
Ebos backs off British purchase, evaluates "significant" Australasian asset
Ebos reports higher profit, looks for acquisitions
Daily ShareChat: EBOS Group